These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 37169994

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of odanacatib in the treatment of postmenopausal women with osteoporosis: a meta-analysis.
    Li J, Qiu Q, Jiang S, Sun J, Pavel V, Li Y.
    J Orthop Surg Res; 2024 Aug 29; 19(1):521. PubMed ID: 39210429
    [Abstract] [Full Text] [Related]

  • 3. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
    Bonnick S, De Villiers T, Odio A, Palacios S, Chapurlat R, DaSilva C, Scott BB, Le Bailly De Tilleghem C, Leung AT, Gurner D.
    J Clin Endocrinol Metab; 2013 Dec 29; 98(12):4727-35. PubMed ID: 24064689
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
    McClung MR, O'Donoghue ML, Papapoulos SE, Bone H, Langdahl B, Saag KG, Reid IR, Kiel DP, Cavallari I, Bonaca MP, Wiviott SD, de Villiers T, Ling X, Lippuner K, Nakamura T, Reginster JY, Rodriguez-Portales JA, Roux C, Zanchetta J, Zerbini CAF, Park JG, Im K, Cange A, Grip LT, Heyden N, DaSilva C, Cohn D, Massaad R, Scott BB, Verbruggen N, Gurner D, Miller DL, Blair ML, Polis AB, Stoch SA, Santora A, Lombardi A, Leung AT, Kaufman KD, Sabatine MS, LOFT Investigators.
    Lancet Diabetes Endocrinol; 2019 Dec 29; 7(12):899-911. PubMed ID: 31676222
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Continuous treatment with odanacatib for up to 8 years in postmenopausal women with low bone mineral density: a phase 2 study.
    Rizzoli R, Benhamou CL, Halse J, Miller PD, Reid IR, Rodríguez Portales JA, DaSilva C, Kroon R, Verbruggen N, Leung AT, Gurner D.
    Osteoporos Int; 2016 Jun 29; 27(6):2099-107. PubMed ID: 26879200
    [Abstract] [Full Text] [Related]

  • 8. Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal Women With Osteoporosis in the Phase 3 Long-Term Odanacatib Fracture Trial.
    Papapoulos S, Bone H, Cosman F, Dempster DW, McClung MR, Nakamura T, Restrepo JFM, Bouxsein ML, Cohn D, de Papp A, Massaad R, Santora A.
    J Bone Miner Res; 2021 Jul 29; 36(7):1225-1234. PubMed ID: 33724542
    [Abstract] [Full Text] [Related]

  • 9. Effects of Odanacatib on Bone Structure and Quality in Postmenopausal Women With Osteoporosis: 5-Year Data From the Phase 3 Long-Term Odanacatib Fracture Trial (LOFT) and its Extension.
    Recker R, Dempster D, Langdahl B, Giezek H, Clark S, Ellis G, de Villiers T, Valter I, Zerbini CA, Cohn D, Santora A, Duong LT.
    J Bone Miner Res; 2020 Jul 29; 35(7):1289-1299. PubMed ID: 32119749
    [Abstract] [Full Text] [Related]

  • 10. Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis--a double-blind, randomized, dose-finding study.
    Nakamura T, Shiraki M, Fukunaga M, Tomomitsu T, Santora AC, Tsai R, Fujimoto G, Nakagomi M, Tsubouchi H, Rosenberg E, Uchida S.
    Osteoporos Int; 2014 Jan 29; 25(1):367-76. PubMed ID: 23716037
    [Abstract] [Full Text] [Related]

  • 11. Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.
    Välimäki MJ, Farrerons-Minguella J, Halse J, Kröger H, Maroni M, Mulder H, Muñoz-Torres M, Sääf M, Snorre Øfjord E.
    Clin Ther; 2007 Sep 29; 29(9):1937-49. PubMed ID: 18035193
    [Abstract] [Full Text] [Related]

  • 12. Effects of odanacatib on bone-turnover markers in osteoporotic postmenopausal women: a post hoc analysis of the LOFT study.
    Duong LT, Clark S, Pickarski M, Giezek H, Cohn D, Massaad R, Stoch SA.
    Osteoporos Int; 2022 Oct 29; 33(10):2165-2175. PubMed ID: 35711006
    [Abstract] [Full Text] [Related]

  • 13. Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study.
    Ishibashi H, Crittenden DB, Miyauchi A, Libanati C, Maddox J, Fan M, Chen L, Grauer A.
    Bone; 2017 Oct 29; 103():209-215. PubMed ID: 28687496
    [Abstract] [Full Text] [Related]

  • 14. Potential role of odanacatib in the treatment of osteoporosis.
    Ng KW.
    Clin Interv Aging; 2012 Oct 29; 7():235-47. PubMed ID: 22866001
    [Abstract] [Full Text] [Related]

  • 15. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial.
    Brixen K, Chapurlat R, Cheung AM, Keaveny TM, Fuerst T, Engelke K, Recker R, Dardzinski B, Verbruggen N, Ather S, Rosenberg E, de Papp AE.
    J Clin Endocrinol Metab; 2013 Feb 29; 98(2):571-80. PubMed ID: 23337728
    [Abstract] [Full Text] [Related]

  • 16. The Safety and Efficacy of Abaloparatide on Postmenopausal Osteoporosis: A Systematic Review and Meta-analysis.
    Xu F, Wang Y, Zhu X.
    Clin Ther; 2024 Mar 29; 46(3):267-274. PubMed ID: 38307725
    [Abstract] [Full Text] [Related]

  • 17. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect.
    Eisman JA, Bone HG, Hosking DJ, McClung MR, Reid IR, Rizzoli R, Resch H, Verbruggen N, Hustad CM, DaSilva C, Petrovic R, Santora AC, Ince BA, Lombardi A.
    J Bone Miner Res; 2011 Feb 29; 26(2):242-51. PubMed ID: 20740685
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of odanacatib treatment for patients with osteoporosis: a meta-analysis.
    Feng S, Luo Z, Liu D.
    J Bone Miner Metab; 2015 Jul 29; 33(4):448-54. PubMed ID: 24996529
    [Abstract] [Full Text] [Related]

  • 19. Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study.
    Langdahl B, Binkley N, Bone H, Gilchrist N, Resch H, Rodriguez Portales J, Denker A, Lombardi A, Le Bailly De Tilleghem C, Dasilva C, Rosenberg E, Leung A.
    J Bone Miner Res; 2012 Nov 29; 27(11):2251-8. PubMed ID: 22777865
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S.
    Clin Ther; 2009 Apr 29; 31(4):751-61. PubMed ID: 19446148
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.